Wall Street analyst estimates for Balchem Corp (BCPC): consensus price target and buy/hold/sell recommendations.
Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry.
Consensus price target
$212.50 (+25 % vs price $169.98)
between $210.00 and $215.00 · 3 targets published in the last quarter
Closing price, Oct 30
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 4 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 10 |
| Avg rating (−2 sell to +2 buy) | 0.60 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-02-19 | $1.41 | ||
| 2026-10-23 | $1.57 | $1.43 | +9.8% |
| 2026-07-31 | $1.40 | $1.27 | +10.2% |
| 2026-04-30 | $1.25 | $1.33 | -6.0% |
| 2026-02-20 | $1.31 | $1.29 | +1.6% |
| 2025-10-21 | $1.35 | $1.36 | -0.7% |
| 2025-07-31 | $1.27 | $1.25 | +1.6% |
| 2025-04-24 | $1.22 | $1.25 | -2.4% |
Valuation Ratios
| P/E Ratio | 33.46 |
| Price / Book | 4.10 |
| EV / EBITDA | 20.03 |
| Dividend Yield | 0.56% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $553.2M | $594.8M | $643.7M | $643.7M | $703.6M | $799.0M | $942.4M | $922.4M | $953.7M | $1.04B |
| Cost of Revenue | $372.3M | $405.8M | $439.4M | $432.3M | $479.7M | $555.8M | $661.9M | $620.4M | $617.5M | $666.5M |
| Gross Profit | $180.9M | $189.0M | $204.3M | $211.4M | $223.9M | $243.2M | $280.5M | $302.1M | $336.2M | $370.6M |
| Research & Development | $7.3M | $9.3M | $11.6M | $11.4M | $10.3M | $13.5M | $12.2M | $15.0M | $16.8M | $18.5M |
| Selling, General & Admin | $82.7M | $82.4M | $84.9M | $97.4M | $102.4M | $102.1M | $123.1M | $130.1M | $136.5M | $142.8M |
| Operating Expenses | $90.0M | $91.8M | $96.5M | $108.8M | $112.8M | $115.7M | $135.3M | $142.9M | $153.3M | $152.3M |
| Operating Income | $90.8M | $96.9M | $107.1M | $102.6M | $111.1M | $127.5M | $145.2M | $159.2M | $182.9M | $218.3M |
| EBITDA | $136.4M | $140.4M | $151.3M | $148.3M | $162.1M | $176.6M | $195.9M | $214.8M | $231.0M | $254.9M |
| Interest Expense | $7.3M | $7.5M | $7.6M | $6.0M | $4.4M | $2.5M | $10.3M | $22.6M | $16.5M | $10.2M |
| Pre-tax Income | $82.9M | $88.5M | $99.0M | $96.5M | $106.4M | $125.2M | $133.7M | $137.3M | $166.5M | $199.0M |
| Income Tax | $27.0M | -$1.6M | $20.5M | $16.8M | $21.8M | $29.1M | $28.4M | $28.7M | $38.0M | $44.2M |
| Net Income | $56.0M | $90.1M | $78.6M | $79.7M | $84.6M | $96.1M | $105.4M | $108.5M | $128.5M | $154.8M |
| EPS | $1.76 | $2.81 | $2.44 | $2.48 | $2.63 | $2.98 | $3.29 | $3.38 | $3.97 | $4.80 |
| EPS (Diluted) | $1.75 | $2.79 | $2.42 | $2.45 | $2.60 | $2.94 | $3.25 | $3.35 | $3.93 | $4.75 |
| Shares Outstanding (Diluted) | 31.9 M | 32.2 M | 32.4 M | 32.5 M | 32.5 M | 32.7 M | 32.4 M | 32.4 M | 32.7 M | 32.6 M |
Price
| Price | $169.98 (closing price, October 30, 2026) |
| Market Cap | $5.4B |
| Exchange | NASDAQ |
| Country | US |
Related companies: HWKN · IOSP · IFF · EMN · INGR · SXT · AVNT · FUL
Explore sector: Basic Materials · Chemicals - Specialty
More sections of BCPC: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks